JPM26: Novo Nordisk reshapes its strategy under new CEO [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
In a presentation at the conference, taking place January 12-15 in San Francisco, Doustdar acknowledged that 2025 was a difficult year for Novo Nordisk, with GLP-1 sales failing to meet expectations. Doustdar outlined Novo Nordisk's strategic 2026 priorities, which included accelerating commercial execution, including rolling out semaglutide 7.2mg, launching the oral Wegovy pill, expanding and mastering cash-pay channels in the US, improving product availability, and continuing the strengthening their R&D pipeline, by bringing in several new assets for obesity and diabetes into the clinic and progressing the late-stage pipeline. Overall, this places Novo Nordisk in a favourable position in the obesity space. Doustdar highlighted the Wegovy pill as a key competitive advantage, launching well ahead of Eli Lilly's orforglipron, and delivering 16.6% weight loss, comparable to injectable Wegovy, which he said no other oral therapy has matched in a Phase III trial. He also pointed to sup
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- ASML Soars Above $500 Billion Value on TSMC's Upbeat Outlook [Yahoo! Finance]Yahoo! Finance
- Eli Lilly: Sell It And Buy Novo Nordisk Instead [Seeking Alpha]Seeking Alpha
- Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk to Keep Pursuing Deals to Expand Obesity Portfolio, CEO Says [Yahoo! Finance]Yahoo! Finance
- AbbVie plans to build out its presence in obesity market [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 12/23/25 - Form 6-K
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- NVO's page on the SEC website